Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03089645 2020-07-27

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

Phase 1 Completed

39 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04073160 2020-07-07

TRIO Bladder

Phase 1 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

NCT01103635 2020-04-07

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Phase 1 Completed

25 enrolled

Dermatologic

Melanoma

NCT02261220 2020-03-06

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Phase 1 Completed

380 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT04274816 2020-02-18

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Phase 1 Completed

13 enrolled

Dermatologic

Melanoma

NCT03005002 2019-12-26

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

Phase 1 Completed

9 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT00702923 2019-11-21

CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

Phase 1 Terminated

12 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

58 enrolled

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT00880854 2019-11-15

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

Phase 1 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

NCT02000947 2019-10-31

D4190C00006

Phase 1 Completed

459 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02705482 2019-08-26

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Phase 1 Completed

58 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT02868632 2019-04-05

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

Phase 1 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT02549651 2019-02-27

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Phase 1 Completed

32 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02141347 2018-12-12

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Phase 1 Completed

65 enrolled

Other solid neoplasmThoracic

Part A and B: Advanced Solid Malignancies

NCT03085849 2018-12-10

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Phase 1 Completed

2 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT02262741 2017-10-23

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Phase 1 Completed

71 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02040064 2016-06-09

GEFTREM

Phase 1 Completed

27 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01334099 2015-06-22

Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients

Phase 1 Terminated

6 enrolled

Breast

Breast Neoplasms

NCT00372853 2012-06-06

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

Phase 1 Completed

28 enrolled

Genitourinary

Carcinoma, Renal Cell

Clinical Trials

IMFINZI-subQ

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

CLOVER

Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases

Induction

Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

TRIO Bladder

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma

Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver

CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer

D4190C00006

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

GEFTREM

Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma